Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Gains from Investment Securities (2020 - 2023)

Historic Gains from Investment Securities for Ovid Therapeutics (OVID) over the last 4 years, with Q4 2023 value amounting to $12000.0.

  • Ovid Therapeutics' Gains from Investment Securities changed N/A to $12000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was $12000.0, marking a year-over-year increase of 20000.0%. This contributed to the annual value of $15.8 million for FY2022, which is 4653.54% up from last year.
  • According to the latest figures from Q4 2023, Ovid Therapeutics' Gains from Investment Securities is $12000.0.
  • In the past 5 years, Ovid Therapeutics' Gains from Investment Securities ranged from a high of $15.8 million in Q1 2022 and a low of -$12000.0 during Q1 2023
  • Over the past 4 years, Ovid Therapeutics' median Gains from Investment Securities value was $1.1 million (recorded in 2020), while the average stood at $4.7 million.
  • As far as peak fluctuations go, Ovid Therapeutics' Gains from Investment Securities surged by 235179.82% in 2022, and later crashed by 10007.6% in 2023.
  • Ovid Therapeutics' Gains from Investment Securities (Quarter) stood at $10.4 million in 2020, then rose by 2.68% to $10.7 million in 2021, then plummeted by 99.89% to $11996.0 in 2022, then increased by 0.03% to $12000.0 in 2023.
  • Its last three reported values are $12000.0 in Q4 2023, -$12000.0 for Q1 2023, and $11996.0 during Q2 2022.